Topic
GLP-1 and incretin drugs
5 reports, newest first.
Semaglutide in diabetic kidney disease: primary MRI outcomes not met in 52-week trial
In a 52-week randomised trial in type 2 diabetes and chronic kidney disease, semaglutide did not significantly alter the coprimary kidney MRI outcomes versus placebo. Some secondary imaging and tissue findings favoured it.
ADA and EASD 2026 consensus: earlier SGLT2 inhibitor and/or GLP-1-based therapy in type 2 diabetes
The updated ADA and EASD consensus widens the focus from glucose control to holistic management and advocates earlier use, possibly from diagnosis, of SGLT2 inhibitors or GLP-1-based therapies.
Oral safiglipron versus dapagliflozin in type 2 diabetes: phase 3 trial in China
In a 32-week phase 3 trial in China, the oral GLP-1 receptor agonist safiglipron was non-inferior to dapagliflozin for HbA1c lowering, with more gastrointestinal side effects.
Chemically synthesised semaglutide HD1916 met equivalence with Wegovy for weight loss in Chinese adults
A 44-week open-label phase III trial in 462 Chinese adults with obesity found HD1916 equivalent to reference semaglutide for body weight reduction, with similar adverse events.
Triple agonist UBT251 lowered body weight over 24 weeks in a phase 2 trial
In a 24-week phase 2 trial of 205 adults with overweight or obesity and without type 2 diabetes, once-weekly UBT251 reduced body weight more than placebo.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.